Scientists 'Resurrect' the Extinct Dire Wolf Using Gene Editing and Ancient DNA
In a groundbreaking feat of science, a team of geneticists at Colossal Biosciences, a biotech company based in Dallas, has successfully brought back to life a version of the long-extinct dire wolf—marking what they describe as the world's first 'successfully de-extincted animal.'
Once a fearsome predator that roamed North America until its extinction around 12,500 years ago, the dire wolf (Aenocyon dirus) has captured popular imagination for decades, most notably as the model for the mythical wolves in HBO's Game of Thrones. Now, scientists say they have revived the animal's appearance and characteristics by genetically engineering gray wolf DNA using ancient samples, cloning technology, and advanced gene editing.
Colossal Biosciences revealed that three pups with dire wolf traits have been born: two males in October 2024 and a female in January 2025. The animals are being housed in a highly secure, undisclosed 2,000-acre facility, equipped with zoo-grade fencing, drone surveillance, and 24-hour monitoring.
The breakthrough involved extracting ancient DNA from two dire wolf fossils—a 13,000-year-old tooth and a 72,000-year-old skull—and using the genetic information to map out the complete genome of the species. Scientists then made precise edits to gray wolf cells, introducing key dire wolf traits such as thicker fur, a broader skull, and powerful jaw structure. A total of 20 edits across 14 genes were made using CRISPR technology.
'These pups carry dire wolf genes, and these genes give them a look that hasn't been seen in over 13,000 years,' said Professor Love Dalén, an evolutionary genomics expert from Stockholm University and an advisor to Colossal. 'This is a huge leap forward—scientifically, this is the closest we've come to reviving an extinct species.'
The hybrid embryos were gestated in domestic dogs, specifically large mixed-breed hounds, with all three pregnancies resulting in healthy births. Though the genome is still 99.9% gray wolf, scientists argue that the defining dire wolf traits justify classifying the animals as a form of de-extinction.
Colossal, which has also announced plans to revive the woolly mammoth, Tasmanian tiger, and dodo, has raised over $435 million since its founding in 2021 by entrepreneur Ben Lamm and renowned Harvard geneticist George Church. The company says it is on track to introduce the first mammoth calves by 2028.
Beyond the dire wolf, Colossal's research has also resulted in cloned litters of red wolves—one of the world's most endangered canid species—using less invasive cloning techniques developed through this project.
While the achievement has sparked excitement, some experts have voiced caution. Critics argue that the funds used for de-extinction could be more effectively directed toward conservation efforts for existing endangered species. Others question the ecological role these animals would play, especially since even modern wolves face political and environmental challenges in the wild.
Still, ethicists like Professor Christopher Preston from the University of Montana believe Colossal is approaching the issue responsibly. 'They've shown strong consideration for animal welfare, with a certified humane facility and thorough genetic screening to avoid harmful mutations,' he said.
Yet the long-term future of the dire wolf remains unclear. While the company hints at future ecological reintegration, many are asking: What role can these resurrected predators realistically serve?
For now, the dire wolf lives again—not in ancient forests or fantasy tales, but in the careful hands of science.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Daily Tribune
08-04-2025
- Daily Tribune
Scientists 'Resurrect' the Extinct Dire Wolf Using Gene Editing and Ancient DNA
In a groundbreaking feat of science, a team of geneticists at Colossal Biosciences, a biotech company based in Dallas, has successfully brought back to life a version of the long-extinct dire wolf—marking what they describe as the world's first 'successfully de-extincted animal.' Once a fearsome predator that roamed North America until its extinction around 12,500 years ago, the dire wolf (Aenocyon dirus) has captured popular imagination for decades, most notably as the model for the mythical wolves in HBO's Game of Thrones. Now, scientists say they have revived the animal's appearance and characteristics by genetically engineering gray wolf DNA using ancient samples, cloning technology, and advanced gene editing. Colossal Biosciences revealed that three pups with dire wolf traits have been born: two males in October 2024 and a female in January 2025. The animals are being housed in a highly secure, undisclosed 2,000-acre facility, equipped with zoo-grade fencing, drone surveillance, and 24-hour monitoring. The breakthrough involved extracting ancient DNA from two dire wolf fossils—a 13,000-year-old tooth and a 72,000-year-old skull—and using the genetic information to map out the complete genome of the species. Scientists then made precise edits to gray wolf cells, introducing key dire wolf traits such as thicker fur, a broader skull, and powerful jaw structure. A total of 20 edits across 14 genes were made using CRISPR technology. 'These pups carry dire wolf genes, and these genes give them a look that hasn't been seen in over 13,000 years,' said Professor Love Dalén, an evolutionary genomics expert from Stockholm University and an advisor to Colossal. 'This is a huge leap forward—scientifically, this is the closest we've come to reviving an extinct species.' The hybrid embryos were gestated in domestic dogs, specifically large mixed-breed hounds, with all three pregnancies resulting in healthy births. Though the genome is still 99.9% gray wolf, scientists argue that the defining dire wolf traits justify classifying the animals as a form of de-extinction. Colossal, which has also announced plans to revive the woolly mammoth, Tasmanian tiger, and dodo, has raised over $435 million since its founding in 2021 by entrepreneur Ben Lamm and renowned Harvard geneticist George Church. The company says it is on track to introduce the first mammoth calves by 2028. Beyond the dire wolf, Colossal's research has also resulted in cloned litters of red wolves—one of the world's most endangered canid species—using less invasive cloning techniques developed through this project. While the achievement has sparked excitement, some experts have voiced caution. Critics argue that the funds used for de-extinction could be more effectively directed toward conservation efforts for existing endangered species. Others question the ecological role these animals would play, especially since even modern wolves face political and environmental challenges in the wild. Still, ethicists like Professor Christopher Preston from the University of Montana believe Colossal is approaching the issue responsibly. 'They've shown strong consideration for animal welfare, with a certified humane facility and thorough genetic screening to avoid harmful mutations,' he said. Yet the long-term future of the dire wolf remains unclear. While the company hints at future ecological reintegration, many are asking: What role can these resurrected predators realistically serve? For now, the dire wolf lives again—not in ancient forests or fantasy tales, but in the careful hands of science.


Daily Tribune
18-02-2025
- Daily Tribune
The Mahfooza Al-Zayani Humanitarian Award Celebrates Champions of Social Work
TDT | Manama The Mahfooza Al-Zayani Humanitarian Award honored the nation's most inspiring figures in community service, celebrating outstanding contributions to humanitarian work in Bahrain. The prestigious accolade, held in a grand ceremony, highlighted the power of giving and the impact of dedicated individuals and teams striving to make a difference. Recognizing Excellence in Humanitarian Work Among the evening's highlights was the posthumous recognition of Sheikha Lulwa bint Mohammed Al Khalifa as Humanitarian Personality of the Year for her enduring legacy in philanthropy and social welfare. The award for Outstanding Student in Humanitarian Work was presented to the IMPACT TEAM from Al Hekma International School, recognizing their dedication to charitable initiatives and social engagement. The Top Winners The competition was fierce, with various teams showcasing their commitment to humanitarian causes: First Place: Sou Khair Team – Ibn Khuldoon School Second Place: Be Prepared Team Third Place: Paramedics Academy Volunteer Team Each of these teams has played a pivotal role in community service, demonstrating remarkable innovation and compassion in their efforts to create lasting change. Sheikha Hind Praises Youth Involvement Speaking exclusively to TDT, Sheikha Hind bint Salman Al Khalifa expressed her admiration for the young participants: 'I'm really proud that this initiative came as an invitation to the youth to show their talent and their eagerness to participate in social work as well as serve the community. I'm very impressed with their approach and the talent they are proudly displaying—they truly deserve this award.' A Night of Inspiration The event also featured a moving speech by Zayed Rashid Al-Zayani, Director General of the Mahfooza Al-Zayani Humanitarian Award, commending the honorees for their selflessness and dedication to serving society. Beyond the awards, the ceremony coincided with a groundbreaking announcement: Bahrain has successfully completed the first-ever international case of sickle cell anemia treatment using CRISPR gene-editing technology. This medical milestone, revealed during a press conference by the Ministry of Health and the Royal Medical Services, cements Bahrain's position at the forefront of global healthcare innovation. With its commitment to both humanitarian excellence and groundbreaking medical achievements, Bahrain continues to shine as a beacon of progress and compassion.


Bahrain News Gazette
18-02-2025
- Bahrain News Gazette
Health Ministry and Royal Medical Services Announce Bahrain's First CRISPR-Based Sickle Cell Treatment Success
Manama: The Ministry of Health and the Royal Medical Services held a press conference highlighting the details of the Kingdom's successful completion of the world's first sickle cell disease patient treatment outside the US using CRISPR-based bone marrow transplantation. According to Bahrain News Agency, the press conference discussing the medical milestone was held at the Crown Prince Centre for Training and Medical Research. It was attended by Dr. Jaleela bint Al Sayed Jawad Hassan, Minister of Health; Brigadier Dr. Shaikh Fahad bin Khalifa bin Salman Al Khalifa, Commander of the Royal Medical Services; Dr. Jamila Mohammed Redha Al Salman, Shura Council member and director of the gene therapy project; and Dr. Noora Mohammed Yusuf Butti, representative of the Bahrain Oncology Centre. The Minister of Health emphasised Bahrain's commitment to medical innovation, with strong support from His Majesty King Hamad bin Isa Al Khalifa and His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister. She noted that Bahrain was among the first countries to approve CRISPR-based gene editing therapy in December 2023, becoming the first in the Middle East and the second globally, after the UK, to authorise its use for sickle cell disease and transfusion-dependent thalassemia. The Minister highlighted Bahrain's ongoing investment in advanced medical infrastructure, facilities, and technology. She noted that the nation's efforts have led to acquiring innovative genetic therapy technology that positively impacted the quality of life for hemoglobinopathy patients. Brigadier Dr. Shaikh Fahad bin Khalifa bin Salman Al Khalifa highlighted the Kingdom of Bahrain's focus on world-class healthcare. He noted that in May 2024, the Bahrain Oncology Centre was accredited by Vertex Pharmaceuticals for bone marrow transplantation and cell cellular therapy. The achievement was made possible through collaboration between the ministry, Government Hospitals, the National Health Regulatory Authority (NHRA), and global partners, including Vertex Pharmaceuticals and CRISPR Therapeutics. Dr. Jamila Mohammed Redha Al Salman, Shura Council member and director of the gene therapy project, highlighted that the modern technology used in the patient's treatment was awarded the Nobel Prize in Chemistry in 2020. She explained that the treatment process involves medical evaluation, stem cell collection, genetic modification using CRISPR, and transplanting the edited cells into the patient. The therapy eliminates symptoms such as pain crises and blood clots, significantly improving quality of life for these patients. Dr. Noora Mohammed Yusuf Butti outlined the different treatment phases the patient underwent as part of the treatment process. The first stage involved patient selection, which required comprehensive medical and psychological evaluations to ensure eligibility in line with the clinical trial results. She explained that the patient then underwent physiological conditioning of the bone marrow through blood exchange in preparation for the transplantation. The third stage involved stem cell collection, where the patient was given medication to stimulate bone marrow production of stem cells. These cells were then collected and sent to specialised centres for genetic modification. Dr. Butti stated that after the genetic editing of the cells, the patient was admitted to the Bahrain Oncology Centre for the conditioning phase where he was administered medication to eliminate old bone marrow prior to the introduction of the genetically edited stem cells. The edited stem cells were then reintroduced into the bloodstream through the arteries, without the need for surgery. The final stage involved the recovery of the bone marrow cells and the patient's full remission from sickle cell disease. Dr Noora emphasised that the entire treatment process, which spans several months, requires full cooperation between the patient and medical team, as well as strict adherence to medical instructions and guidelines for optimal results.